Business Today
Subscribe
ElectionBT ReelsFuel PricesPMS TodayUS NewsIndiaWeatherBT ShortsNRI
EY Business Today Hidden Gems 2026BT MindrushBT India 100
Search
Advertisement
Business News
sun pharma

Sun Pharma

 

More Stories on Sun Pharma
Sun Pharma’s $11.75-billion Organon deal: What it means for Indian pharma M&As

Sun Pharma’s $11.75-billion Organon deal: What it means for Indian pharma M&As

Apr 30, 2026, 01:33 PM IST

Mega acquisition by India’s largest drugmaker comes as peers build cash and expand in specialty therapies.

BT Explainer: Why Sun Pharma’s $11.75-bn Organon deal is priced below past pharma acquisitions

BT Explainer: Why Sun Pharma’s $11.75-bn Organon deal is priced below past pharma acquisitions

Apr 29, 2026, 05:55 PM IST

Lower valuation, balance sheet strength and asset risks shape the deal; analysts draw contrasts with earlier buys by Indian drugmakers

Win-win deal! Sun Pharma jumps 8% in two days with Organon zooming 42% in five days - All about acquisition

Win-win deal! Sun Pharma jumps 8% in two days with Organon zooming 42% in five days - All about acquisition

Apr 28, 2026, 10:21 AM IST

Organon & Co is listed on NYSE and specialises in core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia.

'Buy' Sun Pharma shares: Up to 34% upside? What experts say on India's biggest ever pharma deal Organon

'Buy' Sun Pharma shares: Up to 34% upside? What experts say on India's biggest ever pharma deal Organon

Apr 28, 2026, 10:08 AM IST

Sun Pharma wanted to make a near-complete transition to being a specialty-focused player has been clear over the last five years, though the pace and scale of it was what the Street was wary of.

‘Buy’ Sun Pharma stock after Organon deal - HDFC Securities explains why; share price target

‘Buy’ Sun Pharma stock after Organon deal - HDFC Securities explains why; share price target

Apr 28, 2026, 09:43 AM IST

Following the merger, which is expected to close in early 2027, Organon will be delisted from the New York Stock Exchange (NYSE), the brokerage said.

BT Opening Bell: Sensex slips 330 pts, Nifty below 24,000; SBI, Sun Pharma lead losers

BT Opening Bell: Sensex slips 330 pts, Nifty below 24,000; SBI, Sun Pharma lead losers

Apr 28, 2026, 09:22 AM IST

Among Sensex constituents, State Bank of India (SBI) slipped 1.12% to Rs 1099.40. Sun Pharma declined 0.92%.

Sun Pharma’s $11B Deal & West Asia Stability : What Investors Need To Know Now

Sun Pharma’s $11B Deal & West Asia Stability : What Investors Need To Know Now

Apr 27, 2026, 05:36 PM IST

Sun Pharma’s $11B Deal & West Asia Stability : What Investors Need To Know Now

India’s Biggest Pharma Deal: Everything You Need To Know | What's Hot

India’s Biggest Pharma Deal: Everything You Need To Know | What's Hot

Apr 27, 2026, 05:25 PM IST

Markets kick off the week on a strong note as What’s Hot with Sakshi Batra tracks the biggest buzz on D-Street. From earnings-driven moves in key stocks to sectoral churn, volatility remains the theme amid ongoing global uncertainties, especially US-Iran tensions. The spotlight is firmly on Sun Pharma after its historic $11.7 billion all-cash acquisition of US-based Organon - the largest overseas buy by an Indian pharma company. Market expert Gaurang Shah shares insights on range-bound markets, earnings impact, and sector-specific opportunities across banking, IT, and defence. While pharma leads the rally, IT shows signs of recovery after recent pressure. Investors are advised to stay cautious yet focused on long-term fundamentals as markets navigate global cues, earnings, and evolving geopolitical developments.

BT Closing Bell: Sensex up 639 pts, Nifty at 24,093; Sun Pharma, RIL top gainers; key highlights

BT Closing Bell: Sensex up 639 pts, Nifty at 24,093; Sun Pharma, RIL top gainers; key highlights

Apr 27, 2026, 04:10 PM IST

Stock market today: The key highlight of the session was short covering along with value buying after the recent correction, supported by improved global cues, said an analyst.

Sun Pharma-Organon deal: What the $11.75 billion bet means for China, women’s health and biosimilars

Sun Pharma-Organon deal: What the $11.75 billion bet means for China, women’s health and biosimilars

Apr 27, 2026, 02:41 PM IST

The acquisition gives Sun Pharma entry into China, strengthens its women’s health portfolio and builds a global biosimilars platform.

Sun Pharma Acquires Organon In $11.7 Bn Deal, Enters Global Top 25 Pharma Giants

Sun Pharma Acquires Organon In $11.7 Bn Deal, Enters Global Top 25 Pharma Giants

Apr 27, 2026, 11:43 AM IST

Sun Pharma, India's largest pharma company, has announced the acquisition of US-based Organon in an all-cash deal worth $11.7 billion — the biggest overseas takeover in Indian pharma history. The deal propels Sun Pharma into the global top 25 pharmaceutical companies and the top 3 in women's health. Organon brings over 70 products across 140 markets, adding biosimilars and women's health to Sun Pharma's portfolio. Innovative medicines will now contribute ~27% of revenues, improving margins. While the long-term strategy is compelling, analysts flag integration risks across 150 countries and a short-term debt load of $8.6 billion. The deal is expected to close by early 2027, pending regulatory approvals.

MARKET BUZZ

  • NSE
  • BSE
  • No data found
SUBSCRIBE TO
BUSINESS TODAY MAGAZINE
Subscribe Now
Already a subscriber?Login

TOP VIDEOS